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Abstract Hematopoietic progenitor cells can take up histamine 
or release IL-3-induced histamine through a bi-directional 
transport system that is blocked by H3-receptor antagonists. In 
the present study we demonstrate a correlation between the 
affinity of various H3-receptor antagonists and their potency as 
inhibitors of histamine uptake. All compounds that blocked 
histamine uptake also inhibited IL-3-induced histamine release. 
Yet, classical H3 receptors are not involved in this biological 
activity, since highly specific histamine H3-receptor agonists 
neither alter histamine uptake nor affect the release of 
endogenous histamine synthesized in response to IL-3. Further-
more, the inhibitory effect of H3-receptor antagonists on 
histamine uptake was not reversed by the agonists. Unlike H3-
receptor antagonists, the agonists did not displace the binding of 
the labeled antagonist iodoproxyfan. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Histamine, an ubiquitous mediator of cellular communica-
tion, is produced by a variety of tissues [1]. Most of its bio-
logical functions are exerted through the three membrane re-
ceptor subtypes, Hi, H2 and H3 [2,3]. Intracellular histamine-
binding sites, termed H ^ , have been more recently identified 
in microsomes and nuclei [4,5]. Histamine can also be taken 
up by a specific transport system, similar to the one described 
for other bioamines, such as serotonin and dopamine [6]. This 
take up is temperature-dependent and requires sodium ex-
change for optimal function. It was observed in astrocytes, 
endothelial and glial cells [7-9]. 
We have shown that histamine is also taken up by murine 
hematopoietic progenitor cells. The bone marrow cells (BMC) 
involved are at least partially identical with those synthesizing 
histamine in response to the hematopoietic growth factors IL-
3 or GM-CSF, and calcium ionophore [10-13]. They have 
been characterized as progenitors with partially restricted dif-
ferentiation potential and purified on the basis of their high 
retention of the fluorescent dye rhodamine-123 [10]. Their 
histamine transporter is bi-directional, i.e. the blockade of 
histamine uptake also inhibits the release of newly synthe-
sized, IL-3-induced histamine from BMC, while intracellular 
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histamine levels increase. II-3-dependent cell lines composed 
of immature myeloid cells arrested at a particular stage of the 
differentiation scheme have a similar transport system [14]. 
Based on our previous evidence that the two highly specific 
H3-receptor antagonists carboperamide (MR 16155) and thi-
operamide are very potent inhibitors of histamine uptake by 
hematopoietic progenitor cells [10], our present study ad-
dressed the relationship between classical H3 receptors and 
this histamine transporter. To this end, we tested a number 
of well-defined histamine H3-receptor antagonists and ago-
nists and evaluated their effect on histamine uptake and IL-
3-induced histamine production by murine BMC. 
2. Materials and methods 
2.1. Animals 
Male or female 6-8-week-old C57BL/6 mice were used in all experi-
ments. They were bred under specific pathogen-free conditions in our 
own facilities. 
2.2. Chemicals and drugs 
Histamine dihydrochloride was purchased from Sigma (St. Louis, 
MO) and imetit from RBI (Natick, MA). Carboperamide and (R)ot-
methylhistamine (RaMeHa) were donated by Bioprojet (Paris, 
France). All other H3 antagonists were synthesized by two of us 
(H.S. and W.S.) as described [15-17]. Labeled iodoproxyfan was syn-
thesized according to the method described by Krause (manuscript 
submitted). IL-3 was purchased from R&D (Abingdon, UK). 
2.3. Cell preparations 
BMC were prepared as previously described [10]. The IL-3-depend-
ent FDCP-2 cell line, was grown in RPMI medium (Gibco, Grand 
Island, NY) containing 10% foetal calf serum and 10% WEHI-con-
ditioned medium as a source of IL-3. 
2.4. Membrane preparation 
FDCP-2 cells were harvested and centrifuged. The cell pellet was 
washed in phosphate-buffered saline (PBS) without Ca/Mg (Gibco), 
resuspended in the same buffer and homogenised with a Polytron. 
After centrifugation at 140Xg for 10 min, the supernatant was recen-
trifuged at 23 000Xg for 30 min. The pellet constitutes the membrane 
fraction. It was resuspended in ice-cold buffer and used for all binding 
assays. The protein concentration was determined by using the BCA 
assay (Pearce Chemical, Rockford, IL). 
2.5. Histamine uptake 
The binding experiments on total BMC were performed as previ-
ously described [10]. Each sample was assayed in triplicate and hista-
mine binding, expressed as fmol/106 cells, was calculated from total 
cpm after substraction of non-specific binding determined with 1 uM 
carboperamide. 
2.6. [12b I] iodoproxyfan binding assays 
Aliquots of the membrane suspension (20 ug in 100 ul) were incu-
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Fig. 1. Effect of histamine H3-receptor antagonists on [3H]histamine uptake by bone marrow cells (BMC). Total BMC were incubated for 2 h 
with [3H]histamine (100 nM) with or without indicated antagonists at increasing concentrations. Radioactivity was measured after extensive 
washing. Data represent means ± SEM from 5 to 8 separate experiments. 
bated for 120 min at 37°C with [125I]iodoproxyfan (30 pM) with or 
without competing drugs dissolved in the same phosphate buffer to a 
final volume of 200 ul. Incubations were stopped by repeated (4 times) 
addition of 5 ml of ice-cold medium, followed by rapid filtration 
through glass microfiber filters (GF/C Whatman, Clifton, NJ), pre-
soaked in 0.3% polyethylene-imine. Radioactivity trapped on the fil-
ters was measured by using an LKB (Rockville, MD) gamma-counter. 
Non-specific binding was determined with 1 uM carboperamide. 
2.7. Histamine assay 
Total BMC (2.5xl06/ml) were suspended in culture medium con-
taining 1 ng/ml IL-3, with or without the indicated compounds. They 
were incubated for 24 h in polystyrene tubes (Falcon 2003), centri-
fuged and washed twice in Hanks' balanced salts solution (HBSS, 
Gibco). Histamine concentrations were determined both in superna-
tants and inside the cells lysed by 0.4 N perchloric acid, by using an 
automated continuous flow fluorometric technique previously de-
scribed [18]. 
3. Results and discussion 
The observation that thioperamide and carboperamide, two 
specific histamine H3-receptor antagonists, are potent inhibi-
tors of [3H]histamine uptake by BMC [10], led us to investi-
gate the effect of various other compounds chemically related 
to these antagonists. We found that all those having a potent 
antagonistic effect on H3 receptors also inhibited the interac-
tion between histamine and BMC (Fig. 1). The high-affinity 
H3-receptor antagonists iodoproxyfan, FUB 130 and carbo-
peramide were the most potent inhibitors of tritiated hista-
mine uptake (dose inducing 50% of inhibition IC50 — 4 ± 3, 
8 ± 4 and 30 ± 6 nM, respectively), while low-affinity com-
pounds, like FUB 188 and FUB 135 (data not shown) were 
also less effective in our model. As shown in Fig. 2, the IC50 
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Fig. 2. Affinity of histamine H3-receptor antagonists for their receptor (K[) is correlated with their inhibitory effect on [3H]histamine uptake 
(IQo). The coefficient of correlation was determined by a computing program. References between brackets. FUB 515, FUB 135 and 
FUB 188: X. Ligneau, personal communication. 
S. Corbel et al.lFEBS Letters 404 (1997) 289-293 291 
-8 -7 -6 
Log [drug], M 
<u = . 
= 2 
o £ o e a) o o 
£ o 
carboperamide 
iodoproxyfan 
FUB181 
FUB130 
FUB188 
400 
300-
F ■* 200 
100-
-8 -7 -6 
Log [drug], M 
Fig. 3. Effect of histamine H3-receptor antagonists on histamine production by BMC stimulated with IL-3. Total BMC were incubated with 
IL-3 for 24 h in the presence of the indicated antagonists. A: Histamine was determined in the supernatants. Data represent means ±SEM 
from 5 to 8 separate experiments. B: Histamine assay in pellets. Data represent one typical experiment out of two. 
determined in our study and the K[ value, established by Hs-
receptor classical test ([3H]histamine release from rat cerebral 
cortex synaptosomes [19]), were well correlated. However, 
some discrepancy could be noted: indeed, FUB 181 and 
FUB 130 displayed a similar Kj for H3 receptors, while their 
IC5o were quite different. The same observation applies to 
iodoproxyfan and thioperamide. 
Since histamine transport by hematopoietic progenitors is 
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Fig. 4. Chemical structure of various compounds used in competition experiments. 
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bi-directional [14], we examined whether the compounds that 
blocked histamine uptake also inhibited its release from IL-3-
induced BMC. We found that in the presence of iodoproxy-
fan, carboperamide, FUB 181 or FUB 130 at optimal concen-
tration (10 \iM), bone marrow supernatants contained about 
60% less histamine than controls (Fig. 3A), while intracellular 
histamine levels significantly increased under these conditions 
(Fig. 3B). In contrast, a compound like FUB 188, that did not 
inhibit histamine uptake, did also not modify its secretion in 
response to IL-3 (Fig. 3A,B). The same observation applies to 
a number of other lower-affinity antagonists of histamine H3 
receptors, such as FUB 132 and FUB 135 (data not shown). 
The imidazole moiety may be placed in a suitable position 
only by long spacers between the ring and the lipophilic 
part, as shown before for antagonists interacting with H3 
receptors [15]. 
One possible explanation for the strong inhibitory effect of 
histamine H3-receptor antagonists on histamine uptake by 
BMC could be the fixation of the lipophilic moiety of the 
molecular structure which is common to all antagonists. 
This is, however, not true for all compounds since FUB 515 
(Fig. 4), a lipophilic compound with an imidazole ring sub-
stituted in 4-position which has no H3-antagonist activity does 
neither block histamine binding nor inhibit its IL-3 induced 
release (data not shown). 
Up to this point our data supported the notion that classi-
cal H3 receptors could be involved in the uptake of histamine 
by hematopoietic progenitor cells. This conclusion could not 
be maintained since the H3-receptor agonists imetit [20] and 
(R)oc-methylhistamine [19] whose affinity for histamine H3 
receptors is as high as that of the inhibitory antagonists, do 
not modify histamine uptake [10]. In the same line of evi-
dence, we observed that (R)oc-methylhistamine could not re-
verse the inhibitory effect of iodoproxyfan or carboperamide. 
Indeed, a 1 h preincubation with 1 uM (R)cc-methylhistamine 
neither modified histamine uptake (100 nM) nor altered the 
inhibitory effect of carboperamide or iodoproxyfan (Fig. 5). 
Similar results were obtained with imetit instead of (R)oc-
methylhistamine (data not shown). In addition, the pretreat-
ment with H3 -receptor agonists did not affect the inhibition of 
IL-3-induced histamine production by H3-receptor antago-
nists (data not shown). These findings strengthen the assump-
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Fig. 5. (R)a-methylhistamine does not reverse the inhibition of 
[3H]histamine uptake induced by carboperamide or iodoproxyfan. 
Total BMC were first incubated for 1 h with (R)a-methylhistamine 
(1 |J,M) and [3H]histamine (100 nM) was then added with or with-
out indicated antagonists at two concentrations. Radioactivity was 
measured after extensive washing. Data represent means ± SD from 
two separate experiments done in triplicate. 
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Fig. 6. Concentration-response curve of [125I]iodoproxyfan binding 
on FDCP-2 cell membrane preparation. 20 ug of total crude mem-
branes were incubated for 2 h with increasing concentrations of ra-
dioligand. The non-specific binding was determined in the presence 
of 1 uM carboperamide. Radioactivity was measured after extensive 
washing on fiber glass membranes. Data represent means ± SD from 
three separate experiments. 
tion that the histamine transport system is not mediated by a 
known classical H3 receptor. It seems nonetheless that antag-
onists of the histamine transport system may possess struc-
ture-activity relationships comparable to those of histamine 
H3-receptor antagonists. 
Among all H3-receptor antagonists tested, iodoproxyfan 
was the most potent inhibitor of histamine uptake by BMC. 
Using the radiolabeled form of this compound we could 
indeed demonstrate that it did actually bind both to BMC 
and to the myeloid cell line FDCP-2 which is also capable 
of histamine uptake [10] (data not shown). Similarly, 
[125I]iodoproxyfan (30 pM) binds to crude FDCP-2 membrane 
preparations (19.3 ±3.8 fmol/mg protein) and this binding is 
not inhibited by 1 |xM (R)a-methylhistamine (20.6 ± 2.6 fmol/ 
mg protein; data are means ±SEM from three separate ex-
periments), a concentration which displaces H3-receptor an-
tagonist binding on classical H3 receptors [21]. In contrast, 
carboperamide or thioperamide (1 |0.M) are potent inhibitors 
of [125I]iodoproxyfan (30 pM) binding on FDCP-2 membrane 
preparations (3.8 ±0.9 and 4.5 ±1.6 fmol/mg protein, respec-
tively). As illustrated by Fig. 6, saturation analysis-specific 
[125I]iodoproxyfan binding, defined using 1 |^M carboper-
amide for non-specific binding, led to a Aj of 212 ±39 pM 
and a 5 m a x of 188 ± 19 fmol/mg of protein (means ± SD from 
three separate experiments). 
In conclusion, our data provide evidence for the existence 
of a histamine transporter in murine hematopoietic progenitor 
cells which is clearly distinct from histamine H3 receptors. 
Indeed, histamine uptake was not affected by highly specific 
agonists of this receptor subtype. In contrast the binding sites 
of the transporter were recognized with high affinity by hista-
mine H3-receptor antagonists, such as iodoproxyfan. This in-
teresting feature, together with the occurrence of histamine 
uptake by IL-3-dependent myeloid cell lines, will be very use-
ful for further characterization of this new transport system. 
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